BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33905297)

  • 21. The nature of early-stage endometrial cancer recurrence-A national cohort study.
    Jeppesen MM; Jensen PT; Gilså Hansen D; Iachina M; Mogensen O
    Eur J Cancer; 2016 Dec; 69():51-60. PubMed ID: 27816832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients.
    Binder PS; Peipert JF; Kallogjeri D; Brooks RA; Massad LS; Mutch DG; Powell MA; Thaker PH; McCourt CK
    Am J Obstet Gynecol; 2016 Dec; 215(6):766.e1-766.e9. PubMed ID: 27457116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
    Xiang M; English DP; Kidd EA
    Gynecol Oncol; 2019 Sep; 154(3):487-494. PubMed ID: 31257010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.
    Felix AS; Brasky TM; Cohn DE; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel C; Boggess JF; Pearl ML; Ioffe OB; Deng W; Miller DS; Brinton LA
    Int J Cancer; 2018 Mar; 142(6):1102-1115. PubMed ID: 29063589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of adjuvant therapy in stage IIIC2 endometrial cancer.
    Bogani G; Cappuccio S; Casarin J; Narasimhulu DMM; Cilby WA; Glaser GE; Weaver AL; McGree ME; Keeney GL; Weroha J; Petersen IA; Mariani A
    Int J Gynecol Cancer; 2020 Aug; 30(8):1169-1176. PubMed ID: 32646864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer.
    Long KC; Zhou Q; Hensley ML; Alektiar KM; Gomez J; Gardner GJ; Chi DS; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2012 Apr; 125(1):99-102. PubMed ID: 22112609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
    Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital.
    Prueksaritanond N; Chantape W
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S75-83. PubMed ID: 27266220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Patients With Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer: A Taiwanese Gynecology Oncology Group (TGOG-2005) Retrospective Cohort Study (A STROBE-Compliant Article).
    Chen JR; Chang TC; Fu HC; Lau HY; Chen IH; Ke YM; Liang YL; Chiang AJ; Huang CY; Chen YC; Hong MK; Wang YC; Huang KF; Hsiao SM; Wang PH
    Medicine (Baltimore); 2016 Apr; 95(15):e3330. PubMed ID: 27082583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is the extent of lymphadenectomy a prognostic factor in International Federation of Gynecology and Obstetrics stage II endometrioid endometrial cancer?
    Cuylan ZF; Akilli H; Gungorduk K; Demirkiran F; Oz M; Salman MC; Sozen H; Celik H; Gokcu M; Bese T; Meydanli MM; Ozgul N; Topuz S; Kuscu E; Kuru O; Gokmen S; Gultekin M; Ayhan A
    J Obstet Gynaecol Res; 2021 Mar; 47(3):1134-1144. PubMed ID: 33426779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.
    Brasky TM; Felix AS; Cohn DE; McMeekin DS; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel CI; Boggess JF; Pearl ML; Ioffe OB; Park KJ; Ali S; Brinton LA
    J Natl Cancer Inst; 2017 Mar; 109(3):1-10. PubMed ID: 28376204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.
    Chapman BV; Swanick CW; Ning MS; Allen PK; Soliman PT; Westin SN; Pardeshi V; Broaddus RR; Lu KH; Jhingran A; Eifel PJ; Klopp AH
    Gynecol Oncol; 2019 Jul; 154(1):22-28. PubMed ID: 31109659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study.
    Åkesson Å; Adok C; Dahm-Kähler P
    Gynecol Oncol; 2023 Jan; 168():127-134. PubMed ID: 36434947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
    Casanova J; Duarte GS; da Costa AG; Catarino A; Nave M; Antunes T; Serra SS; Dias SS; Abu-Rustum N; Lima J
    Gynecol Oncol; 2024 Mar; 182():99-107. PubMed ID: 38262245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative thrombocytosis as a prognostic factor in endometrioid-type endometrial carcinoma.
    Abu-Zaid A; Alsabban M; Abuzaid M; AlOmar O; Salem H; Al-Badawi IA
    Ann Saudi Med; 2017; 37(5):393-400. PubMed ID: 28988254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
    Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
    Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
    Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
    Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparable outcome between endometrioid and non-endometrioid tumors in patients with early-stage high-grade endometrial cancer.
    Reynaers EA; Ezendam NP; Pijnenborg JM
    J Surg Oncol; 2015 May; 111(6):790-4. PubMed ID: 25900897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
    Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.